206 related articles for article (PubMed ID: 18787885)
1. Ion transporters involved in acidification of the resorption lacuna in osteoclasts.
Henriksen K; Sørensen MG; Jensen VK; Dziegiel MH; Nosjean O; Karsdal MA
Calcif Tissue Int; 2008 Sep; 83(3):230-42. PubMed ID: 18787885
[TBL] [Abstract][Full Text] [Related]
2. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification.
Henriksen K; Sørensen MG; Nielsen RH; Gram J; Schaller S; Dziegiel MH; Everts V; Bollerslev J; Karsdal MA
J Bone Miner Res; 2006 Jan; 21(1):58-66. PubMed ID: 16355274
[TBL] [Abstract][Full Text] [Related]
3. Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7.
Henriksen K; Gram J; Neutzsky-Wulff AV; Jensen VK; Dziegiel MH; Bollerslev J; Karsdal MA
Biochem Biophys Res Commun; 2009 Jan; 378(4):804-9. PubMed ID: 19070589
[TBL] [Abstract][Full Text] [Related]
4. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
[TBL] [Abstract][Full Text] [Related]
5. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
[TBL] [Abstract][Full Text] [Related]
6. Ion channels and transporters in osteoclasts.
Supanchart C; Kornak U
Arch Biochem Biophys; 2008 May; 473(2):161-5. PubMed ID: 18406337
[TBL] [Abstract][Full Text] [Related]
7. Expression of mouse osteoclast K-Cl Co-transporter-1 and its role during bone resorption.
Kajiya H; Okamoto F; Li JP; Nakao A; Okabe K
J Bone Miner Res; 2006 Jul; 21(7):984-92. PubMed ID: 16813519
[TBL] [Abstract][Full Text] [Related]
8. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
Niikura K; Takeshita N; Takano M
J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the bone phenotype in ClC-7-deficient mice.
Neutzsky-Wulff AV; Karsdal MA; Henriksen K
Calcif Tissue Int; 2008 Dec; 83(6):425-37. PubMed ID: 18958510
[TBL] [Abstract][Full Text] [Related]
10. Membrane-bound carbonic anhydrases in osteoclasts.
Riihonen R; Supuran CT; Parkkila S; Pastorekova S; Väänänen HK; Laitala-Leinonen T
Bone; 2007 Apr; 40(4):1021-31. PubMed ID: 17291844
[TBL] [Abstract][Full Text] [Related]
11. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation.
Schaller S; Henriksen K; Sveigaard C; Heegaard AM; Hélix N; Stahlhut M; Ovejero MC; Johansen JV; Solberg H; Andersen TL; Hougaard D; Berryman M; Shiødt CB; Sørensen BH; Lichtenberg J; Christophersen P; Foged NT; Delaissé JM; Engsig MT; Karsdal MA
J Bone Miner Res; 2004 Jul; 19(7):1144-53. PubMed ID: 15176998
[TBL] [Abstract][Full Text] [Related]
12. A mathematical model of osteoclast acidification during bone resorption.
Marcoline FV; Ishida Y; Mindell JA; Nayak S; Grabe M
Bone; 2016 Dec; 93():167-180. PubMed ID: 27650914
[TBL] [Abstract][Full Text] [Related]
13. Osteoclastic acid transport: mechanism and implications for physiological and pharmacological regulation.
Schlesinger PH; Mattsson JP; Blair HC
Miner Electrolyte Metab; 1994; 20(1-2):31-9. PubMed ID: 8202050
[TBL] [Abstract][Full Text] [Related]
14. The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment.
Schaller S; Henriksen K; Sørensen MG; Karsdal MA
Drug News Perspect; 2005 Oct; 18(8):489-95. PubMed ID: 16391718
[TBL] [Abstract][Full Text] [Related]
15. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
Nyman JK; Väänänen HK
Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
[TBL] [Abstract][Full Text] [Related]
16. Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption.
Sørensen MG; Karsdal MA; Dziegiel MH; Boutin JA; Nosjean O; Henriksen K
BMC Musculoskelet Disord; 2010 Oct; 11():250. PubMed ID: 20977756
[TBL] [Abstract][Full Text] [Related]
17. A quantitative assay for lysosomal acidification rates in human osteoclasts.
Jensen VK; Nosjean O; Dziegiel MH; Boutin JA; Sørensen MG; Karsdal MA; Henriksen K
Assay Drug Dev Technol; 2011 Apr; 9(2):157-64. PubMed ID: 21050068
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.
Laitala T; Väänänen HK
J Clin Invest; 1994 Jun; 93(6):2311-8. PubMed ID: 8200964
[TBL] [Abstract][Full Text] [Related]
19. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
[TBL] [Abstract][Full Text] [Related]
20. ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function.
Lange PF; Wartosch L; Jentsch TJ; Fuhrmann JC
Nature; 2006 Mar; 440(7081):220-3. PubMed ID: 16525474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
